
Advancing Dendritic Cell Immunotherapy for Glioblastoma: Insights from Diakonos Oncology’s Jay Hartenbach
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
-
Narrado por:
-
De:
Acerca de esta escucha
In this episode, Vera spoke with Jay Hartenbach, President and Chief Operating Officer of Diakonos Oncology, a company developing cancer immunotherapies to address the critical and unmet medical need of late-stage and aggressive cancers like glioblastoma.
Jay is a passionate advocate for wellness and innovative healthcare, bringing a unique blend of scientific knowledge, entrepreneurial enthusiasm and business strategy expertise to the Life Sciences industry.
He concurrently serves as the COO of another cancer immunotherapy company, Immunocine. Before moving to biotech, Jay co-founded wellness company Medterra, where he continues to shape the company’s strategic direction as Chairman of the Board. Jay also co-founded Perland Pharmaceuticals, an early-stage biotech company actively developing therapies for arthritis conditions.
Jay has a Masters in Engineering Management from Duke University and a Bachelor of Science in Biomedical Engineering from the University of Miami.
Tune into the episode to hear how Jay is helping drive new frontiers in cancer immunotherapy at Diakonos Oncology through scientific innovation and strategic leadership.
For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media
Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured